FDA green and red lights: May 2024
Breyanzi and Imdelltra head up May’s approvals, while camrelizumab’s CRL is a lowlight.
Breyanzi and Imdelltra head up May’s approvals, while camrelizumab’s CRL is a lowlight.
Supply continues to cause headaches for radiopharmaceutical developers.
An initial winner of the ASCO abstract reveal, Verastem drops a bombshell.
A July meeting with the FDA could determine whether Agenus’s bot-bal combo has a shot at a 2024 filing.
The sale of remaining rights to Allogene ends acrimony between the two companies.